Arvinas (ARVN) Consolidated Net Income (2017 - 2026)

Arvinas' (ARVN) quarterly Consolidated Net Income came in at -$57.6 million in Q1 2026, down 169.48% year-on-year from $82.9 million in Q1 2025, and up 14.54% quarter-over-quarter from -$67.4 million in Q4 2025.

Arvinas (ARVN) Consolidated Net Income (2017 - 2026) Analysis & Trends

Arvinas' Consolidated Net Income history runs 10 years deep, the most recent figure standing at -$57.6 million for Q1 2026.

  • On a quarterly basis, Consolidated Net Income fell 169.48% year-over-year to -$57.6 million in Q1 2026; TTM through Mar 2026 was -$221.3 million, a 374.89% decrease from a year earlier, with the FY2025 full-year figure at -$80.8 million, up 59.38% from the prior year.
  • Consolidated Net Income grew to -$57.6 million in Q1 2026 per ARVN's latest filing, from -$67.4 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $82.9 million in Q1 2025 and bottomed at -$154.8 million in Q4 2023.
  • The 5-year median for Consolidated Net Income is -$63.3 million (2022), against an average of -$57.3 million.
  • Across the five-year window, Consolidated Net Income surged 219.45% in 2025 and sank 169.48% in 2026, its largest moves.
  • Year by year, Consolidated Net Income stood at -$80.1 million in 2022, then slumped by 93.26% to -$154.8 million in 2023, then jumped by 70.87% to -$45.1 million in 2024, then plunged by 49.45% to -$67.4 million in 2025, then advanced by 14.54% to -$57.6 million in 2026.
  • Per Business Quant, the three latest ARVN Consolidated Net Income figures stand at -$57.6 million (Q1 2026), -$67.4 million (Q4 2025), and -$35.1 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Oculis Holding AG 66,140.12 Bn 66,139.83 Bn - -37.09 Mn
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn - -
3 Akari Therapeutics 1,022.34 Bn 1,022.34 Bn - -14.46 Mn
4 BeOne Medicines 472.04 Bn 467.25 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 122.28 Bn 115.03 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 70.07 Bn 61.31 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.66 Bn 62.66 Bn - -26.94 Mn
8 Argenx Se 56.16 Bn 50.98 Bn 1.41 Bn 362.00 Mn
9 Alnylam Pharmaceuticals 37.56 Bn 34.55 Bn 959.66 Mn 205.99 Mn
10 Arvinas 530.56 Mn -84.34 Mn - -57.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -57.60 Mn
Dec 31, 2025 -67.40 Mn
Sep 30, 2025 -35.10 Mn
Jun 30, 2025 -61.20 Mn
Mar 31, 2025 82.90 Mn
Dec 31, 2024 -45.10 Mn
Sep 30, 2024 -49.20 Mn
Jun 30, 2024 -35.20 Mn
Mar 31, 2024 -69.40 Mn
Dec 31, 2023 -154.80 Mn
Sep 30, 2023 -63.90 Mn
Jun 30, 2023 -65.30 Mn
Mar 31, 2023 -80.80 Mn
Dec 31, 2022 -80.10 Mn
Sep 30, 2022 -63.30 Mn
Jun 30, 2022 -67.50 Mn
Mar 31, 2022 -61.10 Mn
Dec 31, 2021 -46.10 Mn
Sep 30, 2021 -46.80 Mn
Jun 30, 2021 -50.30 Mn